RhumbLine Advisers
AGL icon

RhumbLine Advisers’s Agilon Health AGL Stock Holding History

RhumbLine Advisers’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.69M Buy
15,812
+2,246
+17% +$147K ﹤0.01% 2030
2026
Q1 		$107K Sell
13,566
-1,197
-8% -$19.4K ﹤0.01% 3381
2025
Q4 		$254K Sell
14,763
-3,711
-20% -$72K ﹤0.01% 3058
2025
Q3 		$476K Sell
18,474
-59
-0.3% -$2.23K ﹤0.01% 2727
2025
Q2 		$1.07M Buy
18,533
+942
+5% +$75.6K ﹤0.01% 2210
2025
Q1 		$1.9M Buy
17,591
+808
+5% +$70.3K ﹤0.01% 1828
2024
Q4 		$797K Buy
16,783
+976
+6% +$59K ﹤0.01% 2367
2024
Q3 		$1.55M Sell
15,807
-1,514
-9% -$195K ﹤0.01% 2037
2024
Q2 		$2.83M Buy
17,321
+3,383
+24% +$482K ﹤0.01% 1703
2024
Q1 		$2.13M Sell
13,938
-1,324
-9% -$220K ﹤0.01% 1882
2023
Q4 		$4.79M Buy
15,262
+200
+1% +$72.4K 0.01% 1443
2023
Q3 		$6.69M Buy
15,062
+942
+7% +$426K 0.01% 1192
2023
Q2 		$6.12M Buy
14,120
+4,838
+52% +$2.72M 0.01% 1259
2023
Q1 		$5.51M Buy
9,282
+522
+6% +$292K 0.01% 1256
2022
Q4 		$3.54M Buy
8,760
+816
+10% +$383K ﹤0.01% 1488
2022
Q3 		$4.65M Buy
7,944
+577
+8% +$346K 0.01% 1278
2022
Q2 		$4.02M Buy
7,367
+1,491
+25% +$754K 0.01% 1360
2022
Q1 		$3.72M Sell
5,876
-280
-5% -$144K ﹤0.01% 1492
2021
Q4 		$4.16M Buy
6,156
+3,896
+172% +$2.37M 0.01% 1464
2021
Q3 		$1.48M Buy
2,260
+464
+26% +$396K ﹤0.01% 2051
2021
Q2 		$1.82M Buy
+1,796
New +$1.57M ﹤0.01% 1998

Other funds holding AGL

CDR
Clayton Dubilier & Rice New York $895M AUM 792.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
NPCM
North Peak Capital Management New York $900M AUM 193.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $10.3B AUM 29.04% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

RhumbLine Advisers's AGL Position: Q2 2026 in Review

RhumbLine Advisers increased its Agilon Health (AGL) stake by 17% in Q2 2026, buying an estimated $147K and bringing the position to 15,812 shares worth $1.69M. The position accounts for ﹤0.01% of the portfolio, ranked #2030.

RhumbLine Advisers first reported a position in AGL in Q2 2021 and has held it in 21 quarters since. The position peaked at $6.69M in Q3 2023. 179 funds tracked by Wall St. Rank hold AGL as of Q2 2026.

  • RhumbLine Advisers held 15,812 shares of Agilon Health worth $1.69M as of Q2 2026.
  • RhumbLine Advisers bought 2,246 Agilon Health shares in Q2 2026, an estimated $147K.
  • Agilon Health made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #2030 holding.
  • RhumbLine Advisers first reported a position in Agilon Health in Q2 2021 and has held it in 21 quarters since.
  • RhumbLine Advisers's Agilon Health position peaked at $6.69M in Q3 2023.
  • 179 funds tracked by Wall St. Rank held Agilon Health as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.